Edwards Lifesciences (NYSE: EW) and Cogentix Medical (NASDAQ:CGNT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations.

Institutional & Insider Ownership

82.2% of Edwards Lifesciences shares are owned by institutional investors. Comparatively, 12.8% of Cogentix Medical shares are owned by institutional investors. 2.1% of Edwards Lifesciences shares are owned by insiders. Comparatively, 62.7% of Cogentix Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Edwards Lifesciences and Cogentix Medical, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edwards Lifesciences 0 5 15 1 2.81
Cogentix Medical 0 0 2 0 3.00

Edwards Lifesciences currently has a consensus price target of $124.95, indicating a potential upside of 14.27%. Cogentix Medical has a consensus price target of $4.50, indicating a potential upside of 57.34%. Given Cogentix Medical’s stronger consensus rating and higher probable upside, analysts clearly believe Cogentix Medical is more favorable than Edwards Lifesciences.

Profitability

This table compares Edwards Lifesciences and Cogentix Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Edwards Lifesciences 22.47% 27.22% 15.67%
Cogentix Medical -36.14% -11.52% -10.04%

Volatility & Risk

Edwards Lifesciences has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, Cogentix Medical has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.

Earnings and Valuation

This table compares Edwards Lifesciences and Cogentix Medical’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Edwards Lifesciences $2.96 billion 7.81 $569.50 million $3.44 31.78
Cogentix Medical $51.85 million 3.36 -$22.09 million ($0.41) -6.98

Edwards Lifesciences has higher revenue and earnings than Cogentix Medical. Cogentix Medical is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Summary

Edwards Lifesciences beats Cogentix Medical on 10 of the 14 factors compared between the two stocks.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient’s cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.

About Cogentix Medical

Cogentix Medical, Inc. is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB). The Company also offers Macroplastique Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence that is primarily due to intrinsic sphincter deficiency. The PrimeSight flexible endoscopes are used in conjunction with the sterile, single-use microbial barrier known as the EndoSheath Protective Barrier. The PrimeSight endoscopy line also includes rigid endoscopes and portable peripherals, such as the video system and stroboscopy unit.

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.